Wednesday, July 5, 2017

Recordati Rare Diseases Introduces New PANHEMATIN Dosage Strength For Treatment Of Acute Intermittent Porphyria


Recordati Rare Diseases Inc., a biopharmaceutical company committed to providing orphan therapies to underserved rare disease communities in the U.S., today announced the launch of a 350-mg single-vial dosage strength of PANHEMATIN® (hemin for injection) for the amelioration of recurrent attacks of acute intermittent porphyria (AIP).

Source:
www.prnewswire.com/news-releases/recordati-rare-diseases-introduces-new-panhematin-hemin-for-injection-dosage-strength-for-treatment-of-acute-intermittent-porphyria-aip-300482853.html

No comments:

Post a Comment